LSL Pharma Group Inc.
LSL.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 29.90M | 24.82M | 20.59M | 19.18M | 16.62M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.90M | 24.82M | 20.59M | 19.18M | 16.62M |
| Cost of Revenue | 26.19M | 20.85M | 15.71M | 13.48M | 11.74M |
| Gross Profit | 3.71M | 3.97M | 4.88M | 5.70M | 4.88M |
| SG&A Expenses | 6.57M | 5.98M | 5.31M | 4.47M | 3.95M |
| Depreciation & Amortization | 180.70K | 37.80K | 1.80K | 220.80K | 143.40K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.94M | 26.86M | 21.01M | 18.17M | 15.83M |
| Operating Income | -3.04M | -2.05M | -427.00K | 1.01M | 786.60K |
| Income Before Tax | -5.29M | -4.00M | -2.08M | 2.00M | 2.58M |
| Income Tax Expenses | -46.60K | -46.60K | -46.60K | 35.70K | 35.70K |
| Earnings from Continuing Operations | -5.25 | -3.95 | -2.03 | 1.97 | 2.54 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.25M | -3.95M | -2.03M | 1.97M | 2.54M |
| EBIT | -3.04M | -2.05M | -427.00K | 1.01M | 786.60K |
| EBITDA | -1.15M | -400.80K | 961.90K | 2.48M | 2.07M |
| EPS Basic | -0.04 | -0.03 | -0.02 | 0.02 | 0.02 |
| Normalized Basic EPS | -0.03 | -0.02 | -0.01 | 0.00 | 0.00 |
| EPS Diluted | -0.04 | -0.03 | -0.02 | 0.02 | 0.02 |
| Normalized Diluted EPS | -0.03 | -0.02 | -0.01 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 492.84M | 481.64M | 470.44M | 464.57M | 462.07M |
| Average Diluted Shares Outstanding | 492.91M | 481.71M | 470.44M | 464.57M | 462.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |